Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. During the past decades Boehringer Ingelheim conducted or sponsored studies in about 100 countries from all regions of the world.
In compliance with our Policy on Transparency and Publication of Clinical Study Data, Boehringer Ingelheim retrospectively registered in 2014 all clinical trials initiated after January 1, 1998, which were not yet registered on ClinicalTrials.gov.
All new trials including Phase I trials are registered before enrolling the first participant.
Trial synopses are available on this website.
We are committed to disclosing all study results independent of outcome and support responsible sharing of de-identified clinical study data and redacted clinical documents, if data are available in our Clinical Trial Data Database or as reports following the ICH E3 format.
Access is provided after regulatory review has been completed or after termination of the drug development program and once the primary manuscript describing the results has been accepted for publication.